CatalystWireBeta

Share Buyback

In brief · summary, not quotable

EKF Diagnostics Holdings PLC announced a share buyback, purchasing 929,169 ordinary shares at a weighted average price of 27.5269 pence per share on October 17, 2025. The highest price paid per share was 28 pence, and the lowest was 27.5 pence. Following the purchase, the company's total issued share capital will consist of 449,093,790 Ordinary Shares, with 2,655,714 held in treasury, resulting in 446,438,076 Ordinary Shares carrying voting rights. As part of the buyback, EKF acquired 274,000 Ordinary Shares at 27.5 pence per share from Harwood, investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. Following this sale, Mr. Mills' aggregate indirect interest in the Company is 131,650,000 Ordinary Shares.

Full announcement

Select text to share a quote on X · sign in to keep highlights & notes in your EKF notes

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, announces that it has purchased a total of 929,169 of its ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a weighted average price of 7.5269 pence per share. The Ordinary Shares purchased will be held in treasury.

Aggregated information

Date of purchase17 October 2025
Number of Ordinary Shares purchased929,169
Highest price paid per Ordinary Share28p
Lowest price paid per Ordinary Share27.5p
Volume weighted average price paid27.5269p
Transaction details
Number of Ordinary Shares purchasedTransaction price (GBp)Time of transactionTrading venue
50,00028p09:02:28AIMX
605,16927.5p10:51:43AIMX
274,00027.5p11:56:56AIMX

Total voting rights

Following the purchase, the Company's total issued share capital will consist of 449,093,790 Ordinary Shares, of which 2,655,714 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 446,438,076. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

PDMR dealing

As part of the buyback and within the above aggregate purchase, EKF acquired 274,000 Ordinary Shares in total at a price of 28 pence per Ordinary Share from Harwood as investment manager to Oryx International Growth Fund Limited ("Oryx") and North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"). EKF acquired 91,333 and 182,667 Ordinary Shares from Oryx and NASCIT respectively. Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.

Following the above sale of Ordinary Shares by Oryx and NASCIT to the Company, Mr. Mills' aggregate indirect interest in the Company is 131,650,000 Ordinary Shares.

Additional disclosures relating to this PDMR dealing are detailed below.

The person responsible for arranging the release of this Announcement

on behalf of the Company is Julian Baines, Executive Chair.

EKF Diagnostics Holdings plcwww.ekfdiagnostics.com
Julian Baines, Executive Chairvia Walbrook PR
Gavin Jones, Chief Executive Officer
Singer Capital Markets (Nominated Adviser & Broker)Tel: +44 (0)20 7496 3000
Phil Davies / Oliver Platts
Walbrook PR LimitedTel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Alice WoodingsMob: +44 (0)7980 541 893 / +44 (0) 7407 804 654
a)NameChristopher Mills
2Reason for the notification
a)Position/statusNon-Executive Director
b)Initial notification /AmendmentInitial Notification
a)NameEKF Diagnostics Holdings plc
b)LEI213800DXTF3EAUK1AR05
a)Description of the financial instrument, type of instrumentOrdinary Shares of 1 pence each
Identification codeGB0031509804
b)Nature of the transactionDisposal of Ordinary Shares
c)Price(s) and volume(s)
Price(s)Volume(s)
27.5p274,000
d)Aggregated information
- Aggregated volumen/a
- Price
e)Date of the transaction17 October 2025
f)Place of the transactionLondon Stock Exchange, AIMX

Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note